Abstract
DNA methylation profiling has been suggested a reliable technique to distinguish between benign and malignant adrenocortical tumors, a process which with current diagnostic methods remains challenging and lacks diagnostic accuracy of borderline tumors. Accurate distinction between benign and malignant adrenal tumors is of the essence, since ACC is a rare but aggressive endocrine disease with an annual incidence of about 2.0 cases per million people per year. The estimated five-year overall survival rate for ACC patients is
Original language | English |
---|---|
Article number | 1218 |
Number of pages | 21 |
Journal | Cancers |
Volume | 12 |
Issue number | 5 |
DOIs | |
Publication status | Published - May 2020 |
Keywords
- adrenocortical carcinoma
- epigenetics
- DNA methylation
- ISLAND METHYLATOR PHENOTYPE
- GROWTH-FACTOR RECEPTOR
- EUROPEAN NETWORK
- DNA METHYLATION
- GENOMIC CHARACTERIZATION
- PROMOTER METHYLATION
- PROGNOSTIC ROLE
- ADRENAL-TUMORS
- FACTOR-I
- EXPRESSION